Alumis inc
Officers & Directors
Martin Babler, age 61, serves as President, Chief Executive Officer, and Chairman of the Board. Mark Bradley, age 61, has been Chief Development Officer since May 2021; he previously held senior roles at The Bristol-Myers Squibb Company, MyoKardia, Inc., and Genentech, Inc., and holds an M.A. and B.A. from the University of California, Berkeley. Jörn Drappa, M.D., Ph.D., age 61, has been Chief Medical Officer and Head of Research and Development since September 2022; his prior experience includes positions at Viela Bio, Inc., MedImmune (AstraZeneca plc), and Genentech, Inc.; he earned his M.D. and Ph.D. from the University of Cologne and completed postgraduate studies at Cornell Medical School/Hospital for Special Surgery. David M. Goldstein, Ph.D., age 60, has served as Chief Scientific Officer since September 2021; he previously worked at Principia Biopharma Inc. and Roche Holding AG; he holds a Ph.D. in chemistry from the University of Virginia and a B.A. in chemistry from Franklin and Marshall College. Roy Hardiman, age 66, has been Chief Business and Strategy Officer since January 2025; he was formerly Chief Business Officer and Chief Legal Officer at Principia Biopharma Inc., a director at Pharmacyclics Inc., and held leadership roles at Genentech, Inc.; he holds a J.D. from the University of California, Los Angeles School of Law, and an M.A. in Biology and B.A. in pharmacology from the University of California, Santa Barbara. John Schroer, age 60, has been Chief Financial Officer since May 2022; he previously served as CFO at ArsenalBio Inc. and Translate Bio, Inc. Sanam Pangali, age 42, is Chief Legal Officer and Corporate Secretary.
Alumis inc currently has 224 employees.
|
